Eye rosacea study seeks safer antibiotic use
NCT ID NCT05296837
First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This study looks at how different doses of the antibiotic doxycycline affect antibiotic resistance in people with ocular rosacea, an inflammatory eye condition. Researchers will compare a low anti-inflammatory dose (40 mg daily) with a standard antibiotic dose (200 mg daily) and a placebo. The goal is to see which dose causes the least resistance in gut bacteria, helping guide safer long-term treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- doxycycline
- What this could lead to
- If successful, this study could help doctors choose the safest doxycycline dose for ocular rosacea, reducing the risk of antibiotic resistance.
- What could go wrong
- This is a small, early-phase study focused on measuring resistance, not on treating symptoms. Results may not change current practice directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIMICROBIAL RESISTANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Farncisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mass antibiotic dosing could save thousands of children in niger
- Rapid molecular tests could help doctors prescribe antibiotics more precisely
- Scientists track superbug genes in pneumonia patients
- Could a sleep hormone help fight superbugs?
- New eye gel could ease rosacea symptoms
- Metaphor messages boost antibiotic smarts in parents